To register for the Free SmallCapReview Newsletter visit http://www.smallcapreview.com.
Ireland Inc. (OTCBB: IRLD) Closed at $0.50. Today announced that results from its technical program have indicated that Ireland has a new gold discovery at its Columbus Project located in Esmeralda County, Nevada.
Bulk Leach Test Results Indicate Significant Gold and Silver Extraction Rates
Ireland has received results from an independent laboratory that was commissioned to complete a bulk leach test on 1,738 pounds of material extracted from the permitted mine area (Zone A) of Ireland's Columbus Project. The bulk material assayed 0.055 ounces per ton ("opt") gold (Au) and 0.520 opt silver (Ag). The leach test extracted 0.047 opt Au and 0.464 opt Ag into solution. The precious metals were then collected on resins and processed to produce Au and Ag bullion for a net extraction of 0.038 opt Au and 0.385 opt Ag. This represents leach extraction of 86.2% of Au into solution and 69.1% of Au recovered as metal. The overall extraction was 0.043 opt Au equivalent. Upon completion of the test, the precious metal beads were delivered to Ireland. The Company will commission further testing in order to optimize net metal recovery.
What They Do: Ireland Inc. (IRLD) ("Ireland") is a minerals exploration and development company that is focused on the discovery and extraction of precious metals from mineral deposits in the Southwestern United States.
In 2007, Ireland acquired rights to two mining properties, both of which are prospective for gold and other minerals. In early 2008, Ireland completed the acquisition of the Columbus Project located near Tonopah, NV, where it has an option to acquire an additional 22,640 acres of adjacent mineral claims. Ireland also owns rights to acquire up to 100% of the Red Mountain Project in San Bernardino County, California.
Oxygen Biotherapeutics (OTCBB: OXBO) Closed at $0.22. Today announced that the company has received a letter from the FDA that outlines what the agency termed a "path forward" as a basis to resume clinical studies of Oxycyte in TBI. Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier.
The letter was in response to the company's request for formal dispute resolution that was submitted to the FDA Ombudsman's office. As a result, the Office of Blood Research and Review examined the reviewing division's decision to delay the start of a proposed Phase II dose escalation study of Oxycyte in traumatic brain injury (TBI).
"This outcome of the review is of great relief to us," said Chris J. Stern, company chairman and CEO. "It is helpful because it now positions the FDA to participate with the company in the development of the recommended experimental protocols to ensure their alignment with the agency's suggested path forward. This gives us the best chance to demonstrate safety of Oxycyte sufficient to move ahead in TBI in the United States," said Stern.
What They Do: Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte®) and an implantable glucose sensor.
Neoprobe Corporation (OTCBB: NEOP) Closed at $0.55. Today announced that a multicenter Phase 3 study of Lymphoseek has reached the accrual of 203 lymph nodes, the study’s primary accrual objective. The multi-center open label study has been conducted in patients with either breast cancer or melanoma. Based upon a review of the preliminary data from the study, the primary efficacy end-point of the study was achieved.
David Bupp, Neoprobe’s President and CEO, said, “Neoprobe is pleased to announce this successful accrual milestone in the first Phase 3 study of Lymphoseek (NEO3-05). In the Phase 2 multi-center study of Lymphoseek, which was conducted in patients with breast cancer or melanoma, an overall localization rate of 94% in lymph nodes was achieved in those patients where both a patent blue dye and Lymphoseek were used. A similar concordance rate of 94% was established by Neoprobe and FDA as the primary efficacy objective for the Phase 3 trial, NEO3-05. Based upon the intraoperative worksheets and preliminary pathology reports, we believe that the primary efficacy end-point of NEO3-05 has been achieved and no incidents related to drug safety have been reported in the Lymphoseek studies. Upon completion of a full analysis of the Phase 3 data, we will provide a complete update on the study results after all clinical data has been reviewed by our internal clinical team and external consultants. We expect full data will be available in the 2nd quarter of 2009. We intend to hold a conference call to discuss the full trial results when the study reviews have been completed.”
What They Do: Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients.
ProUroCare Medical Inc. (OTCBB: PUMD) Closed at $0.50. Today announced that the physician at one of three major participating centers has completed his portion (ten patients) of the study of the ProUroScan prostate imaging system. The study is intended to identify images of the prostate. The results from these clinical trials will be used to support ProUroCare’s future application to the Food and Drug Administration for 510(k) clearance of the ProUroScan system.
ProUroCare’s Chief Executive Officer, Rick Carlson, stated, “We believe that the basic mapping and data maintenance claim being studied accurately reflects the current needs of the market and the capabilities of the system. The center completing the study achieved results that exceeded those presented in our last peer reviewed article in the journal Urology, March 2008. While preliminary, we believe this bodes well for the future of the ProUroScan technology. We applaud this physician and his staff for their commitment and diligent efforts in completing their portion of the clinical study.”
Overview of Clinical Study
We believe the ProUroScan system, when used for basic mapping and data maintenance will be regulated as a Class II device and cleared through a 510(k) application. Our protocol calls for a 40-patient clinical trial involving participation by four different physicians. In addition to the recently completed study, a second physician has begun his patient trials, and two more are expected to begin their studies in the near future.
What They Do: ProUroCare Medical Inc. is a development stage company engaged in the business of developing for market innovative products for the detection and characterization of urological prostate disease. Currently, the Company’s primary focus is the ProUroScan prostate imaging system, which is now in clinical trials.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com.
